Top

Published in:

01-05-2024 | Cancer Immunotherapy | Review Article

Comprehensive review of the repositioning of non-oncologic drugs for cancer immunotherapy

Authors: Abdur Rauf, Payal B. Joshi, Ahmed Olatunde, Nabia Hafeez, Zubair Ahmad, Hassan A. Hemeg, Abdullah S. M. Aljohani, Waleed Al Abdulmonem, Muthu Thiruvengadam, Dhivya Viswanathan, Govindasamy Rajakumar, Rekha Thiruvengadam

Published in: Medical Oncology | Issue 5/2024

Abstract

Drug repositioning or repurposing has gained worldwide attention as a plausible way to search for novel molecules for the treatment of particular diseases or disorders. Drug repurposing essentially refers to uncovering approved or failed compounds for use in various diseases. Cancer is a deadly disease and leading cause of mortality. The search for approved non-oncologic drugs for cancer treatment involved in silico modeling, databases, and literature searches. In this review, we provide a concise account of the existing non-oncologic drug molecules and their therapeutic potential in chemotherapy. The mechanisms and modes of action of the repurposed drugs using computational techniques are also highlighted. Furthermore, we discuss potential targets, critical pathways, and highlight in detail the different challenges pertaining to drug repositioning for cancer immunotherapy.

Graphical abstract

Olatunde A, Nigam M, Singh RK, Panwar AS, Lasisi A, Alhumaydhi FA, Jyoti kumar V, et al. Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs. Cancer Cell Int. 2021;21(1):499. https://doi.org/10.1186/s12935-021-02202-5.CrossRefPubMedPubMedCentral

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Fu L, Jin W, Zhang J, Zhu L, Lu J, Zhen Y, et al. Repurposing non-oncology small-molecule drugs to improve cancer therapy: current situation and future directions. Acta Pharm Sin B. 2022;12(2):532–57. https://doi.org/10.1016/j.apsb.2021.09.006.CrossRefPubMed

Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med. 2017;177(11):1569–75. https://doi.org/10.1001/jamainternmed.2017.3601.CrossRefPubMedPubMedCentral

Kaushik I, Ramachandran S, Prasad S, Srivastava SK. Drug rechanneling: a novel paradigm for cancer treatment. Semin Cancer Biol. 2021;68:279–90. https://doi.org/10.1016/j.semcancer.2020.03.011.CrossRefPubMed

Aggarwal S, Verma SS, Aggarwal S, Gupta SC. Drug repurposing for breast cancer therapy: Old weapon for new battle. Semin Cancer Biol. 2021;68:8–20. https://doi.org/10.1016/j.semcancer.2019.09.012.CrossRefPubMed

Basso J, Miranda A, Sousa J, Pais A, Vitorino C. Repurposing drugs for glioblastoma: from bench to bedside. Cancer Lett. 2018;428:173–83. https://doi.org/10.1016/j.canlet.2018.04.039.CrossRefPubMed

Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129(10):1275–83. https://doi.org/10.1182/blood-2016-09-736686.CrossRefPubMedPubMedCentral

Dimopoulos MA, Kastritis E. Thalidomide for myeloma: still here? Lancet Haematol. 2018;5(10):e439–40. https://doi.org/10.1016/S2352-3026(18)30154-6.CrossRefPubMed

10.

Liu Q, Tong D, Liu G, Gao J, Wang LA, Xu J, et al. Metformin inhibits prostate cancer progression by targeting tumor-associated inflammatory infiltration. Clin Cancer Res. 2018;24(22):5622–34. https://doi.org/10.1158/1078-0432.CCR-18-0420.CrossRefPubMed

11.

Raju TN. The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98). The Lancet. 2000;355(9208):1022. https://doi.org/10.1016/s0140-6736(05)74775-9.CrossRef

12.

Kresge N, Simoni RD, Hill RL. The rational design of nucleic acid inhibitors to treat leukemia: the work of George H. Hitchings. J Biol Chem. 2008;283(18):e10–11.CrossRef

13.

Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov. 2006;5(12):993–6. https://doi.org/10.1038/nrd2199.CrossRefPubMed

14.

Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6(1):201. https://doi.org/10.1038/s41392-021-00572-w.CrossRefPubMedPubMedCentral

15.

Gonzalez-Fierro A, Dueñas-González A. Drug repurposing for cancer therapy, easier said than done. Semin Cancer Biol. 2021;68:123–31. https://doi.org/10.1016/j.semcancer.2019.12.012.CrossRefPubMed

16.

Medema MH, Fischbach MA. Computational approaches to natural product discovery. Nat Chem Biol. 2015;11(9):639–48. https://doi.org/10.1038/nchembio.1884.CrossRefPubMedPubMedCentral

17.

Baltz RH. Natural product drug discovery in the genomic era: realities, conjectures, misconceptions, and opportunities. J Ind Microbiol Biotechnol. 2019;46(3–4):281–99. https://doi.org/10.1007/s10295-018-2115-4.CrossRefPubMed

18.

Hur M, Campbell AA, Almeida-de-Macedo M, Li L, Ransom N, Jose A, et al. A global approach to analysis and interpretation of metabolic data for plant natural product discovery. Nat Prod Rep. 2013;30(4):565–83. https://doi.org/10.1039/c3np20111b.CrossRefPubMedPubMedCentral

19.

Biermann F, Wenski SL, Helfrich EJN. Navigating and expanding the roadmap of natural product genome mining tools. Beilstein J Org Chem. 2022;18:1656–71. https://doi.org/10.3762/bjoc.18.178.CrossRefPubMedPubMedCentral

20.

Cui W, Aouidate A, Wang S, Yu Q, Li Y, Yuan S. Discovering anti-cancer drugs via computational methods. Front Pharmacol. 2020;11:733. https://doi.org/10.3389/fphar.2020.00733.CrossRefPubMedPubMedCentral

21.

Prada-Gracia D, Huerta-Yépez S, Moreno-Vargas LM. Application of computational methods for anticancer drug discovery, design, and optimization. Bol Med Hosp Infant Mex. 2016;73(6):411–23. https://doi.org/10.1016/j.bmhimx.2016.10.006.CrossRefPubMedPubMedCentral

22.

Baldi A. Computational approaches for drug design and discovery: an overview. Syst Rev Pharm. 2010;1(1):99–105. https://doi.org/10.4103/0975-8453.59519.CrossRef

23.

Sahu A, Prabhash K, Noronha V, Joshi A, Desai S. Crizotinib: a comprehensive review. South Asian J Cancer. 2013;2(2):91–97. https://doi.org/10.4103/2278-330X.110506.CrossRefPubMedPubMedCentral

24.

Selassie C, Verma RP. History of quantitative structure-activity relationships. Burger’s Med Chem Drug Discov. 2003;1:1–48. https://doi.org/10.1002/0471266949.bmc001.pub2.CrossRef

25.

Mendenhall J, Meiler J. Improving quantitative structure-activity relationship models using Artificial Neural Networks trained with dropout. J Comput Aided Mol Des. 2016;30(2):177–89. https://doi.org/10.1007/s10822-016-9895-2.CrossRefPubMedPubMedCentral

26.

Esposito EX, Hopfinger AJ, Madura JD. Methods for applying the quantitative structure-activity relationship paradigm. Methods Mol Biol. 2004;275:131–214. https://doi.org/10.1385/1-59259-802-1:131.CrossRefPubMed

27.

Morris GM, Lim-Wilby M. Molecular docking. Methods Mol Biol. 2008;443:365–82. https://doi.org/10.1007/978-1-59745-177-2_19.CrossRefPubMed

28.

Fan J, Fu A, Zhang L. Progress in molecular docking. Quant Biol. 2019;7:83–9. https://doi.org/10.1007/s40484-019-0172-y.CrossRef

29.

Yuriev E, Ramsland PA. Latest developments in molecular docking: 2010-2011 in review. J Mol Recognit. 2013;26(5):215–39. https://doi.org/10.1002/jmr.2266.CrossRefPubMed

30.

Dias R, de Azevedo Jr WF. Molecular docking algorithms. Curr Drug Targets. 2008;9(12):1040–7. https://doi.org/10.2174/138945008786949432.CrossRefPubMed

31.

Bhattarai D, Singh S, Jang Y, Hyeon Han S, Lee K, Choi Y. An insight into drug repositioning for the development of novel anti-cancer drugs. Curr Top Med Chem. 2016;16(19):2156–68. https://doi.org/10.2174/1568026616666160216153618.CrossRefPubMed

32.

Zhang Z, Zhou L, Xie N, Nice EC, Zhang T, Cui Y, et al. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther. 2020;5(1):113. https://doi.org/10.1038/s41392-020-00213-8.CrossRefPubMedPubMedCentral

33.

Du JH, Zhang HD, Ma ZJ, Ji KM. Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother Pharmacol. 2010;65(5):895–902. https://doi.org/10.1007/s00280-009-1095-5.CrossRefPubMed

34.

Zhou X, Sun WJ, Wang WM, Chen K, Zheng JH, Lu MD, et al. Artesunate inhibits the growth of gastric cancer cells through the mechanism of promoting oncosis both in vitro and in vivo. Anticancer Drugs. 2013;24(9):920–7. https://doi.org/10.1097/CAD.0b013e328364a109.CrossRefPubMed

35.

Jiang W, Huang Y, Wang JP, Yu XY, Zhang LY. The synergistic anticancer effect of artesunate combined with allicin in osteosarcoma cell line in vitro and in vivo. Asian Pac J Cancer Prev. 2013;14(8):4615–9. https://doi.org/10.7314/apjcp.2013.14.8.4615.CrossRefPubMed

36.

Wang Q, Wu LM, Li AY, Zhao Y, Wang NP. Experimental studies of antitumor effect of artesunate on liver cancer. Zhongguo Zhong Yao Za Zhi. 2001;26(10):707–8, 720 (Chinese).PubMed

37.

Freire Boullosa L, Van Loenhout J, Flieswasser T, De Waele J, Hermans C, Lambrechts H, et al. Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer. Redox Biol. 2021;42:101949. https://doi.org/10.1016/j.redox.2021.101949.CrossRefPubMedPubMedCentral

38.

Cui XY, Park SH, Park WH. Auranofin inhibits the proliferation of lung cancer cells via necrosis and caspase-dependent apoptosis. Oncol Rep. 2020;44(6):2715–24. https://doi.org/10.3892/or.2020.7818.CrossRefPubMed

39.

Pearson K, Jensen H, Kander T, Schött U. Desmopressin in vitro effects on platelet function, monitored with Multiplate, ROTEM and Sonoclot. Scand J Clin Lab Investig. 2016;76(4):282–90. https://doi.org/10.3109/00365513.2016.1149615.CrossRef

40.

Benavente MA, Bianchi CP, Imperiale F, Aba MA. Antiproliferative effects of oxytocin and desmopressin on canine mammary cancer cells. Front Vet Sci. 2016;3:119. https://doi.org/10.3389/fvets.2016.00119.CrossRefPubMedPubMedCentral

41.

Fagone P, Donia M, Mangano K, Quattrocchi C, Mammana S, Coco M, et al. Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer cells. Basic Clin Pharmacol Toxicol. 2013;112(1):63–69. https://doi.org/10.1111/j.1742-7843.2012.00923.x.CrossRefPubMed

42.

Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol. 2005;56(1):47–60. https://doi.org/10.1016/j.critrevonc.2004.09.009.CrossRefPubMed

43.

Imrali A, Mao X, Yeste-Velasco M, Shamash J, Lu Y. Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin. Am J Cancer Res. 2016;6(8):1772–84.PubMedPubMedCentral

44.

Gruppuso PA, Boylan JM, Sanders JA. The physiology and pathophysiology of rapamycin resistance: implications for cancer. Cell Cycle. 2011;10(7):1050–8. https://doi.org/10.4161/cc.10.7.15230.CrossRefPubMedPubMedCentral

45.

Fuchs R, Stracke A, Holzmann V, Luschin-Ebengreuth G, Meier-Allard N, Ebner N, et al. Prazosin induced lysosomal tubulation interferes with cytokinesis and the endocytic sorting of the tumour antigen CD98hc. Biochim Biophys Acta Mol Cell Res. 2018;1865(9):1211–29. https://doi.org/10.1016/j.bbamcr.2018.06.006.CrossRefPubMed

46.

An M, Ma WH, Jia HW, Li YW, Feng JJ, Meng J, et al. Prazosin inhibits the growth and mobility of osteosarcoma cells. Transl Cancer Res. 2019;8(5):1997–2004. https://doi.org/10.21037/tcr.2019.09.03.CrossRefPubMedPubMedCentral

47.

Guo YC, Chang CM, Hsu WL, Chiu SJ, Tsai YT, Chou YH, et al. Indomethacin inhibits cancer cell migration via attenuation of cellular calcium mobilization. Molecules. 2013;18(6):6584–96. https://doi.org/10.3390/molecules18066584.CrossRefPubMedPubMedCentral

48.

Wang Z, Chen Y, Zheng R, Qin D, Chen X, Wang Y, et al. In vitro effects of prostaglandin E2 or indomethacin on the proliferation of lymphokine-activated killer cells and their cytotoxicity against bladder tumor cells in patients with bladder cancer. Prostaglandins. 1997;54(5):769–79. https://doi.org/10.1016/s0090-6980(97)00161-5.CrossRefPubMed

49.

Tilaoui M, Mouse HA, Jaafari A, Zyad A. Differential effect of artemisinin against cancer cell lines. Nat Prod Bioprospect. 2014;4(3):189–96. https://doi.org/10.1007/s13659-014-0024-4.CrossRefPubMedPubMedCentral

50.

Wong YK, Xu C, Kalesh KA, He Y, Lin Q, Wong WSF, et al. Artemisinin as an anticancer drug: recent advances in target profiling and mechanisms of action. Med Res Rev. 2017;37(6):1492–517. https://doi.org/10.1002/med.21446.CrossRefPubMed

51.

Kimura T, Takabatake Y, Takahashi A, Isaka Y. Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res. 2013;73(1):3–7. https://doi.org/10.1158/0008-5472.CAN-12-2464.CrossRefPubMed

52.

Ciftci H, Sever B, Ocak F, Bayrak N, Yıldız M, Yıldırım H, et al. In vitro and in silico study of analogs of plant product plastoquinone to be effective in colorectal cancer treatment. Molecules. 2022;27(3):693. https://doi.org/10.3390/molecules27030693.CrossRefPubMedPubMedCentral

53.

Chen YH, Wu JX, Yang SF, Chen ML, Chen TH, Hsiao YH. Metformin potentiates the anticancer effect of everolimus on cervical cancer in vitro and in vivo. Cancers (Basel). 2021;13(18):4612. https://doi.org/10.3390/cancers13184612.CrossRefPubMed

54.

Mussin N, Oh SC, Lee KW, Park MY, Seo S, Yi NJ, et al. Sirolimus and metformin synergistically inhibits colon cancer in vitro and in vivo. J Korean Med Sci. 2017;32(9):1385–95. https://doi.org/10.3346/jkms.2017.32.9.1385.CrossRefPubMedPubMedCentral

55.

Wiggins HL, Wymant JM, Solfa F, Hiscox SE, Taylor KM, Westwell AD, et al. Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells. Biochem Pharmacol. 2015;93(3):332–42. https://doi.org/10.1016/j.bcp.2014.12.014.CrossRefPubMedPubMedCentral

56.

Deng K, Shen J, Wang W, Li M, Li H, Chen C, et al. Sodium chloride (NaCl) potentiates digoxin-induced anti-tumor activity in small cell lung cancer. Cancer Biol Ther. 2019;20(1):52–64. https://doi.org/10.1080/15384047.2018.1504723.CrossRefPubMed

57.

Wang Y, Ma Q, Zhang S, Liu H, Zhao B, Du B, et al. Digoxin enhances the anticancer effect on non-small cell lung cancer while reducing the cardiotoxicity of adriamycin. Front Pharmacol. 2020;11:186. https://doi.org/10.3389/fphar.2020.00186.CrossRefPubMedPubMedCentral

58.

Das S, Tripathi N, Preet R, Siddharth S, Nayak A, Bharatam PV, et al. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade. Oncotarget. 2017;8(1):248–67. https://doi.org/10.18632/oncotarget.11335.CrossRefPubMed

59.

Samanta A, Ravindran G, Sarkar A. Quinacrine causes apoptosis in human cancer cell lines through caspase-mediated pathway and regulation of small-GTPase. J Biosci. 2020;45:43. https://doi.org/10.1007/s12038-020-0011-3.CrossRefPubMed

60.

Montgomery A, Adeyeni T, San K, Heuertz RM, Ezekiel UR. Curcumin sensitizes silymarin to exert synergistic anticancer activity in colon cancer cells. J Cancer. 2016;7(10):1250–7. https://doi.org/10.7150/jca.15690.CrossRefPubMedPubMedCentral

61.

Sufi SA, Adigopula LN, Syed SB, Mukherjee V, Coumar MS, Rao HS, et al. In-silico and in-vitro anti-cancer potential of a curcumin analogue (1E, 6E)-1, 7-di (1H-indol-3-yl) hepta-1, 6-diene-3, 5-dione. Biomed Pharmacother. 2017;85:389–98. https://doi.org/10.1016/j.biopha.2016.11.040.CrossRefPubMed

62.

Saeed MEM, Yücer R, Dawood M, Hegazy MF, Drif A, Ooko E, et al. In silico and in vitro screening of 50 curcumin compounds as EGFR and NF-κB inhibitors. Int J Mol Sci. 2022;23(7):3966. https://doi.org/10.3390/ijms23073966.CrossRefPubMedPubMedCentral

63.

Toden S, Tran HM, Tovar-Camargo OA, Okugawa Y, Goel A. Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer. Oncotarget. 2016;7(13):16158–71. https://doi.org/10.18632/oncotarget.7567.CrossRefPubMedPubMedCentral

64.

Chung SS, Vadgama JV. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling. Anticancer Res. 2015;35(1):39–46.PubMedPubMedCentral

65.

Chatterjee K, AlSharif D, Mazza C, Syar P, Al Sharif M, Fata JE. Resveratrol and pterostilbene exhibit anticancer properties involving the downregulation of HPV oncoprotein E6 in cervical cancer cells. Nutrients. 2018;10(2):243. https://doi.org/10.3390/nu10020243.CrossRefPubMedPubMedCentral

66.

Carter LG, D’Orazio JA, Pearson KJ. Resveratrol and cancer: focus on in vivo evidence. Endocr Relat Cancer. 2014;21(3):R209–25. https://doi.org/10.1530/ERC-13-0171.CrossRefPubMedPubMedCentral

67.

Oliveira PM, Lopes TZ, Tedesco AC, Rahal P, Calmon MF. Effect of berberine associated with photodynamic therapy in cell lines. Photodiagn Photodyn Ther. 2020;32:102045. https://doi.org/10.1016/j.pdpdt.2020.102045.CrossRef

68.

Aleissa MS, Al-Zharani M, Alneghery LM, Aleissa AM. Berberine enhances the sensitivity of radiotherapy in ovarian cancer cell line (SKOV-3). Saudi Pharm J. 2023;31(1):110–8. https://doi.org/10.1016/j.jsps.2022.11.009.CrossRefPubMed

69.

Liu X, Ji Q, Ye N, Sui H, Zhou L, Zhu H, et al. Berberine inhibits invasion and metastasis of colorectal cancer cells via COX-2/PGE2 mediated JAK2/STAT3 signaling pathway. PLoS ONE. 2015;10(5):e0123478. https://doi.org/10.1371/journal.pone.0123478.CrossRefPubMedPubMedCentral

70.

Wang K, Zhang C, Bao J, Jia X, Liang Y, Wang X, et al. Synergistic chemopreventive effects of curcumin and berberine on human breast cancer cells through induction of apoptosis and autophagic cell death. Sci Rep. 2016;6:26064. https://doi.org/10.1038/srep26064.CrossRefPubMedPubMedCentral

71.

Qu H, Song X, Song Z, Jiang X, Gao X, Bai L, et al. Berberine reduces temozolomide resistance by inducing autophagy via the ERK1/2 signaling pathway in glioblastoma. Cancer Cell Int. 2020;20(1):592. https://doi.org/10.1186/s12935-020-01693-y.CrossRefPubMedPubMedCentral

72.

Samadi P, Sarvarian P, Gholipour E, Asenjan KS, Aghebati-Maleki L, Motavalli R, et al. Berberine: a novel therapeutic strategy for cancer. IUBMB Life. 2020;72(10):2065–79. https://doi.org/10.1002/iub.2350.CrossRefPubMed

73.

Choi SB, Bae GS, Jo IJ, Song HJ, Park SJ. Effects of berberine on acute necrotizing pancreatitis and associated lung injury. Pancreas. 2017;46(8):1046–55. https://doi.org/10.1097/MPA.0000000000000877.CrossRefPubMed

74.

Spagnuolo C, Russo GL, Orhan IE, Habtemariam S, Daglia M, Sureda A, et al. Genistein and cancer: current status, challenges, and future directions. Adv Nutr. 2015;6(4):408–19. https://doi.org/10.3945/an.114.008052.CrossRefPubMedPubMedCentral

75.

Zhou S, Wu H, Ning W, Wu X, Xu X, Ma Y, et al. Ivermectin has new application in inhibiting colorectal cancer cell growth. Front Pharmacol. 2021;12:717529. https://doi.org/10.3389/fphar.2021.717529.CrossRefPubMedPubMedCentral

76.

Dominguez-Gomez G, Chavez-Blanco A, Medina-Franco JL, Saldivar-Gonzalez F, Flores-Torrontegui Y, Juarez M, et al. Ivermectin as an inhibitor of cancer stem-like cells. Mol Med Rep. 2018;17(2):3397–403. https://doi.org/10.3892/mmr.2017.8231.CrossRefPubMed

77.

Aftab BT, Dobromilskaya I, Liu JO, Rudin CM. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res. 2011;71(21):6764–72. https://doi.org/10.1158/0008-5472.CAN-11-0691.CrossRefPubMedPubMedCentral

78.

Lan K, Yan R, Zhu K, Li W, Xu Z, Dang C, et al. Itraconazole inhibits the proliferation of gastric cancer cells in vitro and improves patient survival. Oncol Lett. 2018;16(3):3651–7. https://doi.org/10.3892/ol.2018.9072.CrossRefPubMedPubMedCentral

79.

Barbosa EJ, Löbenberg R, de Araujo GLB, Bou-Chacra NA. Niclosamide repositioning for treating cancer: challenges and nano-based drug delivery opportunities. Eur J Pharm Biopharm. 2019;141:58–69. https://doi.org/10.1016/j.ejpb.2019.05.004.CrossRefPubMed

80.

Shangguan F, Liu Y, Ma L, Qu G, Lv Q, An J, et al. Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics. J Cancer. 2020;11(12):3454–66. https://doi.org/10.7150/jca.41418.CrossRefPubMedPubMedCentral

81.

Gold A, Eini L, Nissim-Rafinia M, Viner R, Ezer S, Erez K, et al. Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response. Oncogene. 2019;38(17):3103–18. https://doi.org/10.1038/s41388-018-0654-9.CrossRefPubMed

82.

Albinger N, Hartmann J, Ullrich E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. 2021;28(9):513–27. https://doi.org/10.1038/s41434-021-00246-w.CrossRefPubMedPubMedCentral

83.

Pantziarka P, Verbaanderd C, Sukhatme V, Rica Capistrano I, Crispino S, Gyawali B, et al. ReDO_DB: the repurposing drugs in oncology database. Ecancermedicalscience. 2018;6(12):886. https://doi.org/10.3332/ecancer.2018.886.CrossRef

84.

Rajkumar SV. Thalidomide in multiple myeloma. Oncology (Williston Park). 2000;14(12 Suppl 13):11–6.PubMed

85.

Zweegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GM, Levin MD, et al. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood. 2016;127(9):1109–16. https://doi.org/10.1182/blood-2015-11-679415.CrossRefPubMed

Title: Comprehensive review of the repositioning of non-oncologic drugs for cancer immunotherapy
Authors: Abdur Rauf
Payal B. Joshi
Ahmed Olatunde
Nabia Hafeez
Zubair Ahmad
Hassan A. Hemeg
Abdullah S. M. Aljohani
Waleed Al Abdulmonem
Muthu Thiruvengadam
Dhivya Viswanathan
Govindasamy Rajakumar
Rekha Thiruvengadam
Publication date: 01-05-2024
Publisher: Springer US
Keyword: Cancer Immunotherapy
Published in: Medical Oncology / Issue 5/2024
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-024-02368-8

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Graphical abstract

Please log in to get access to this content

Other articles of this Issue 5/2024

Unlocking the potential: phenylboronic acid as a nuclear-targeting boron agent for neutron capture therapy

Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies

Chlordiazepoxide against signalling, receptor and regulatory proteins of breast cancer: a structure-based in-silico approach

Estrogen-receptor status determines differential regulation of α1- and α2-adrenoceptor-mediated cell survival, angiogenesis, and intracellular signaling responses in breast cancer cell lines

Increased V-ATPase activity can lead to chemo-resistance in oral squamous cell carcinoma via autophagy induction: new insights

A novel α,β-unsaturated ketone inhibits leukemia cell growth as PARP1 inhibitor

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage